Maynard Um
-
-
-
-
-
-
-
Celcuity Inc (CELC) PT Lowered to $140 at Needham
-
-
-
-
-
-
-
Celcuity (CELC) Reiterated at Buy by Stifel on Revtorpyk Approval
-
-
-
-
-
-
-
Celcuity reports positive Phase 3 trial results for gedatolisib in breast cancer
-
-
-
-
-
-
-
Increasing unusual option volume: TPG XRX FXY CGNX MRAM CRNC CELC SIMO
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Celcuity Inc (CELC)
-
-
-
-
-
-
-
Wolfe Research: 'We'd be buyers of CELC on any weakness related to the external catalyst'
-
-
-
-
-
-
-
Increasing unusual call option volume: EQG CELC BBD FE CWAN
-
453,913 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

